KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors

May 31, 2023

Myeloma Investment Fund portfolio company KAHR, a clinical-stage biotech company developing DSP107, a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive immunity to treat solid tumors and blood cancers, today announced positive results from the dose escalation Phase I study of DSP107 in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. The results will be presented as a poster in the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6, in Chicago, IL.